My watch list  

Sun Pharma Announces USFDA Tentative Approval for Generic Cymbalta


Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules.

These generic duloxetine hydrochloride delayed-release capsules, 20 mg (base), 30 mg (base), and 60 mg (base) are indicated in the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) and Diabetic Peripheral Neuropathic Pain (DPNP).

Facts, background information, dossiers
More about Sun Pharmaceutical Industries
More about FDA
  • News

    Merck and Pfizer receive FDA approval for kidney cancer therapy

    Merck and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) in combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This is the first FDA approval for an anti-PD-L1 therapy as part o ... more

    FDA Accepts File for Cladribine Tablets as Potential Treatment for Relapsing Forms of MS

    Merck announced that a resubmission of the New Drug Application (NDA) for cladribine tablets as a potential treatment for patients with relapsing forms of multiple sclerosis (MS) has been accepted for filing by the U.S. Food and Drug Administration (FDA). “We are delighted the FDA has accep ... more

    Do not try CRISPR at home

    Gene therapy is the administration of genetic material to modify or manipulate the expression of a gene product or to alter the biological properties of living cells for therapeutic use. Gene therapies offer the potential to treat diseases or conditions for which no or few treatments exist. ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE